The Company continues to anticipate that the totality of its early-stage research programs will comprise less than 20% of overall expenditure.

ARIKAYCE ® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million-- --NDA for ...